These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38302398)

  • 1. Prognostic value of anti-IFI16 autoantibodies in pulmonary arterial hypertension and mortality in patients with systemic sclerosis.
    Perurena-Prieto J; Callejas-Moraga EL; Sanz-Martínez MT; Colobran R; Guillén-Del-Castillo A; Simeón-Aznar CP
    Med Clin (Barc); 2024 Apr; 162(8):370-377. PubMed ID: 38302398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel autoantigen to differentiate limited cutaneous systemic sclerosis from diffuse cutaneous systemic sclerosis: the interferon-inducible gene IFI16.
    Mondini M; Vidali M; De Andrea M; Azzimonti B; Airò P; D'Ambrosio R; Riboldi P; Meroni PL; Albano E; Shoenfeld Y; Gariglio M; Landolfo S
    Arthritis Rheum; 2006 Dec; 54(12):3939-44. PubMed ID: 17133607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of anti-IFI16 antibodies by ELISA: clinical and serological associations in systemic sclerosis.
    Costa S; Mondini M; Caneparo V; Afeltra A; Airò P; Bellisai F; Faggioli P; Gerli R; Lotzniker M; Meroni PL; Morozzi G; Radice A; Riccieri V; Scarsi M; Sebastiani GD; Sinico RA; Tincani A; Gariglio M; Landolfo S
    Rheumatology (Oxford); 2011 Apr; 50(4):674-81. PubMed ID: 21134960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and Survival of Anti-U1 RNP Antibody-Positive Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.
    Sobanski V; Giovannelli J; Lynch BM; Schreiber BE; Nihtyanova SI; Harvey J; Handler CE; Denton CP; Coghlan JG
    Arthritis Rheumatol; 2016 Feb; 68(2):484-93. PubMed ID: 26415038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
    Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
    Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
    Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
    Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
    Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
    Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
    Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis.
    Becker MO; Kill A; Kutsche M; Guenther J; Rose A; Tabeling C; Witzenrath M; Kühl AA; Heidecke H; Ghofrani HA; Tiede H; Schermuly RT; Nickel N; Hoeper MM; Lukitsch I; Gollasch M; Kuebler WM; Bock S; Burmester GR; Dragun D; Riemekasten G
    Am J Respir Crit Care Med; 2014 Oct; 190(7):808-17. PubMed ID: 25181620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-PM-Scl antibody in patients with systemic sclerosis.
    Koschik RW; Fertig N; Lucas MR; Domsic RT; Medsger TA
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S12-6. PubMed ID: 22261302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole blood viscosity in systemic sclerosis: a potential biomarker of pulmonary hypertension?
    Senturk B; Akdeniz B; Yilmaz MB; Ozcan Kahraman B; Acar B; Uslu S; Birlik M
    Clin Rheumatol; 2020 Jan; 39(1):49-56. PubMed ID: 31129792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
    Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
    Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-RNA polymerase III antibodies in systemic sclerosis: Multicentric study from Argentina.
    Gargiulo MLÁ; Perez N; Khoury M; Buhl M; Suárez L; Sarano J; Montoya F; Bazzalo I; Navarro S; Pendón G; Molina MJ; Mamani M; Rivero M; Gómez G
    Reumatol Clin (Engl Ed); 2022; 18(6):368-373. PubMed ID: 34366290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
    Hamaguchi Y
    J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement.
    Mitri GM; Lucas M; Fertig N; Steen VD; Medsger TA
    Arthritis Rheum; 2003 Jan; 48(1):203-9. PubMed ID: 12528120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoantibodies in systemic sclerosis and their clinical correlation in patients from a Midwestern region of Brazil].
    Coelho Horimoto AM; da Costa IP
    Rev Bras Reumatol; 2015; 55(3):229-39. PubMed ID: 25559063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China.
    Hu S; Hou Y; Wang Q; Li M; Xu D; Zeng X
    Arthritis Res Ther; 2018 Oct; 20(1):235. PubMed ID: 30348207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease.
    Gunn J; Pauling JD; McHugh NJ
    Clin Rheumatol; 2014 Jun; 33(6):869-71. PubMed ID: 24752346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis.
    Perosa F; Favoino E; Cuomo G; Digiglio L; Dammacco F; Prete M; Valentini G; Racanelli V
    Arthritis Res Ther; 2013 Jul; 15(4):R72. PubMed ID: 23837651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.